Startups
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars.
Overview
Employees
501-1000
Founded date
2012
Mentions in press and media 17
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 3, 2026 | Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires | |
| Jul 23, 2026 | Samsung Biologics Reports Second Quarter 2026 Financial Results | Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion Delivered stable business performance through continued disciplined execution Expanded global presence while advancing innovation and future growth ini... |
| Jul 16, 2026 | Samsung Bioepis Grows Australia Biosimilar Portfolio to Four as PBS Default Reform Nears | By Henry Baker Published: Jul 16 2026, 11:01 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jun 25, 2026 | ATLATL and Samsung Bioepis Launch 'Samsung Bioepis Innovation Prize C-Lab Outside' to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific | Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies SHANGHAI, June 25, 2026 /PRNewswire/ -- ATLATL Innovation Center ("ATLATL"), a global innovation platfor... |
| Nov 27, 2025 | Phrontline Biopharma: $60 Million Raised To Advance Development Of Next-Generation ADC Programs | Phrontline Biopharma has closed a $60 million Pre-A+ financing round that will significantly expand the company’s global development of bispecific and dual-payload antibody drug conjugates. Lapam Investment led the round with participation ... |
| Nov 3, 2025 | Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO | Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Sams... |
| Jul 23, 2025 | Samsung Biologics reports second quarter 2025 financial results | Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July... |
| May 22, 2025 | Samsung BioLogics spin-off to separate contract drug making, new growth drivers | SEOUL :South Korean drug maker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies, to help allay customer concerns about conflicts of interest between businesses. BioLog... |
| May 17, 2025 | Redica Systems and Hyundai ADM Bio: Navigating the Future of Life Sciences | In the fast-paced world of life sciences, two companies are making headlines for their strategic maneuvers. Redica Systems, a quality and regulatory intelligence firm, has secured funding to enhance its innovative platform. Meanwhile, Hyund... |
Show more
Reviews 0
FAQ about SAMSUNG BIOEPIS
When was SAMSUNG BIOEPIS founded?
SAMSUNG BIOEPIS was founded in 2012.
What has the press written about SAMSUNG BIOEPIS?
Parsers VC has collected 17 articles mentioning SAMSUNG BIOEPIS, among them “Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires” (Nov 3, 2026) and “Samsung Biologics Reports Second Quarter 2026 Financial Results” (Jul 23, 2026).
Is SAMSUNG BIOEPIS still active?
SAMSUNG BIOEPIS is probably closed: its latest activity on Parsers VC dates from Nov 6, 2026.